Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13834462 | 0.87 | TDP1 (0.39) | TDP1NT5EP2RY2P2RY12P2RY4 | |
| SCHEMBL2718172 | 0.83 | GSTP1 (0.35) | GSTP1 | |
| SCHEMBL16991400 | 0.81 | TDP1 (0.40) | TDP1NT5EP2RY2P2RY12MEN1 | |
| SCHEMBL17831310 | 0.81 | TDP1 (0.40) | TDP1NT5EP2RY2P2RY12MEN1 | |
| SCHEMBL16991403 | 0.81 | TDP1 (0.40) | TDP1NT5EP2RY2P2RY12MEN1 | |
| SCHEMBL14929374 | 0.80 | TDP1 (0.41) | TDP1NT5EP2RY2P2RY12P2RY4 | |
| SCHEMBL14946311 | 0.80 | TDP1 (0.41) | TDP1NT5EP2RY2P2RY12P2RY4 | |
| SCHEMBL2718175 | 0.79 | ACHE (0.43) | TDP1NT5E | |
| SCHEMBL13722826 | 0.78 | TDP1 (0.37) | TDP1P2RY2P2RY4P2RY6 | |
| SCHEMBL2719694 | 0.77 | PRMT6 (0.46) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088746-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8030467-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7750131-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7666854-B2 | Bis-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-7547684-B2 | 5′-modified bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121045-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | TDP1 211/4885NT5E 149/4885P2RY2 4213/4885 |
| US-20090156792-A1 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NSUN2, ADAR, POLRMT | TDP1 211/4885NT5E 149/4885P2RY2 4213/4885 |
| US-20100184966-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | TDP1 233/4885NT5E 21/4885P2RY2 2768/4885 |
| US-20090192302-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | TDP1 233/4885NT5E 21/4885P2RY2 2768/4885 |
| US-20070287831-A1 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS | NT5C3B, NSUN2, ADAR | TDP1 233/4885NT5E 21/4885P2RY2 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.